

# Alexander C. Ford

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/656134/publications.pdf>

Version: 2024-02-01

522  
papers

30,409  
citations

3515

90  
h-index

5806

161  
g-index

547  
all docs

547  
docs citations

547  
times ranked

19311  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 712-721.e4.	2.4	1,624
2	Prevalence of, and Risk Factors for, Chronic Idiopathic Constipation in the Community: Systematic Review and Meta-analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 1582-1591.	0.2	645
3	Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 1547-1561.	0.2	595
4	The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. <i>Gut</i> , 2010, 59, 325-332.	6.1	588
5	Probiotic <i>Bifidobacterium longum</i> NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2017, 153, 448-459.e8.	0.6	542
6	Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 644-659.	0.2	523
7	American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation. <i>American Journal of Gastroenterology</i> , 2014, 109, S2-S26.	0.2	503
8	Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. <i>Gut</i> , 2009, 58, 367-378.	6.1	486
9	<i>Helicobacter pylori</i> eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. <i>BMJ</i> , The, 2014, 348, g3174-g3174.	3.0	477
10	Prevalence of Symptoms Meeting Criteria for Irritable Bowel Syndrome in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2012, 107, 1474-1482.	0.2	475
11	Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 661-673.	0.2	469
12	Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2008, 337, a2313-a2313.	2.4	454
13	Irritable Bowel Syndrome. <i>New England Journal of Medicine</i> , 2017, 376, 2566-2578.	13.9	439
14	Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1044-1060.	1.9	423
15	Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. <i>Gut</i> , 2018, 67, 430-440.	6.1	397
16	Functional Dyspepsia. <i>New England Journal of Medicine</i> , 2015, 373, 1853-1863.	13.9	361
17	Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. <i>Gut</i> , 2015, 64, 1049-1057.	6.1	360
18	Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 908-917.	3.7	359

#	ARTICLE	IF	CITATIONS
19	Pathophysiology of irritable bowel syndrome. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 133-146.	3.7	358
20	Irritable bowel syndrome. <i>Lancet, The</i> , 2020, 396, 1675-1688.	6.3	348
21	Effect of Antidepressants and Psychological Therapies, Including Hypnotherapy, in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 1350-1365.	0.2	335
22	Effect of Gender on Prevalence of Irritable Bowel Syndrome in the Community: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2012, 107, 991-1000.	0.2	320
23	Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. <i>Gut</i> , 2011, 60, 209-218.	6.1	312
24	Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1279-1286.	2.4	306
25	Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2019, 114, 21-39.	0.2	303
26	Opportunistic Infections With Anti-Tumor Necrosis Factor- $\alpha$ Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials. <i>American Journal of Gastroenterology</i> , 2013, 108, 1268-1276.	0.2	295
27	Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 389-400.	1.9	285
28	A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPS Diet in Treating Symptoms of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2018, 113, 1290-1300.	0.2	269
29	Glucocorticosteroid Therapy in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 590-599.	0.2	266
30	American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2018, 113, 1-18.	0.2	262
31	The Effect of Fiber Supplementation on Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 1367-1374.	0.2	258
32	Bi-directionality of Brain-Gut Interactions in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2018, 154, 1635-1646.e3.	0.6	258
33	Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 359-370.	3.7	256
34	Global burden of irritable bowel syndrome: trends, predictions and risk factors. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 473-486.	8.2	248
35	Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report. <i>Gastroenterology</i> , 2018, 154, 1140-1171.e1.	0.6	247
36	Efficacy of 5-HT <sub>3</sub> Antagonists and 5-HT <sub>4</sub> Agonists in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2009, 104, 1831-1843.	0.2	235

#	ARTICLE	IF	CITATIONS
37	Gastroparesis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 41.	18.1	235
38	Functional dyspepsia. <i>Lancet, The</i> , 2020, 396, 1689-1702.	6.3	235
39	Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 601-616.	0.2	231
40	<i>Helicobacter pylori</i> eradication therapy to prevent gastric cancer: systematic review and meta-analysis. <i>Gut</i> , 2020, 69, 2113-2121.	6.1	231
41	Yield of Diagnostic Tests for Celiac Disease in Individuals With Symptoms Suggestive of Irritable Bowel Syndrome. <i>Archives of Internal Medicine</i> , 2009, 169, 651.	4.3	216
42	Functional gastrointestinal disorders: advances in understanding and management. <i>Lancet, The</i> , 2020, 396, 1664-1674.	6.3	216
43	Efficacy of Immunosuppressive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 630-642.	0.2	212
44	Effect of psychological therapy on disease activity, psychological comorbidity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 189-199.	3.7	212
45	British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. <i>Gut</i> , 2021, 70, 1214-1240.	6.1	212
46	Systematic review: the effects of fibre in the management of chronic idiopathic constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 895-901.	1.9	211
47	Cough in the community: a cross sectional survey and the relationship to gastrointestinal symptoms. <i>Thorax</i> , 2006, 61, 975-979.	2.7	204
48	Chronic constipation. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17095.	18.1	203
49	Irritable Bowel Syndrome: A 10-Yr Natural History of Symptoms and Factors That Influence Consultation Behavior. <i>American Journal of Gastroenterology</i> , 2008, 103, 1229-1239.	0.2	194
50	The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 632-642.	3.7	186
51	Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 144-158.	1.9	185
52	Systematic Review and Meta-analysis of the Prevalence of Irritable Bowel Syndrome in Individuals With Dyspepsia. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 401-409.	2.4	173
53	World Gastroenterology Organisation Global Guidelines. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 467-478.	1.1	173
54	Efficacy of 5-Aminosalicylates in Crohn's Disease: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 617-629.	0.2	170

#	ARTICLE	IF	CITATIONS
55	Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: A meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 853-867.	0.6	168
56	What Is the Prevalence of Clinically Significant Endoscopic Findings in Subjects With Dyspepsia? Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 830-837.e2.	2.4	166
57	Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. <i>Journal of Gastroenterology</i> , 2011, 46, 421-431.	2.3	166
58	Validation of the Rome III Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care. <i>Gastroenterology</i> , 2013, 145, 1262-1270.e1.	0.6	163
59	Eradication Therapy in Helicobacter pylori Positive Peptic Ulcer Disease: Systematic Review and Economic Analysis. <i>American Journal of Gastroenterology</i> , 2004, 99, 1833-1855.	0.2	155
60	Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 3-11.	1.9	155
61	Epidemiology of <i>Helicobacter pylori</i> infection and Public Health Implications. <i>Helicobacter</i> , 2010, 15, 1-6.	1.6	146
62	Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor therapy in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 447-458.	1.9	144
63	Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 240-248.	1.9	144
64	Ethnicity, Gender, and Socioeconomic Status as Risk Factors for Esophagitis and Barrett's Esophagus. <i>American Journal of Epidemiology</i> , 2005, 162, 454-460.	1.6	143
65	Prevalence of Irritable Bowel Syndrome-type Symptoms in Patients With Celiac Disease: A Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 359-365.e1.	2.4	141
66	Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis. <i>Gut</i> , 2017, 66, 411-420.	6.1	137
67	Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. <i>Gut</i> , 2020, 69, 1441-1451.	6.1	137
68	Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 549-561.	1.9	136
69	Population screening and treatment of Helicobacter pylori infection. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 230-240.	8.2	136
70	Efficacy of Oral vs. Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2012, 107, 167-176.	0.2	130
71	Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis. <i>Gut</i> , 2008, 57, 1545-1553.	6.1	124
72	Helicobacter pylori Test and Treatment or Endoscopy for Managing Dyspepsia: An Individual Patient Data Meta-analysis. <i>Gastroenterology</i> , 2005, 128, 1838-1844.	0.6	122

#	ARTICLE	IF	CITATIONS
73	Ulcerative colitis. <i>BMJ</i> , The, 2013, 346, f432-f432.	3.0	122
74	Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. <i>Gut</i> , 2020, 69, 74-82.	6.1	122
75	Optimum duration of regimens for <i>Helicobacter pylori</i> eradication. <i>The Cochrane Library</i> , 2013, , CD008337.	1.5	120
76	Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis. <i>Gastroenterology</i> , 2018, 155, 1753-1763.	0.6	119
77	Poor Correlation Between Clinical Disease Activity and Mucosal Inflammation, and the Role of Psychological Comorbidity, in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, 541-551.	0.2	117
78	Screening for Celiac Disease in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis. <i>American Journal of Gastroenterology</i> , 2017, 112, 65-76.	0.2	117
79	Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 143-153.	0.6	116
80	Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. <i>Gut</i> , 2022, 71, 1117-1126.	6.1	115
81	Eradication therapy for peptic ulcer disease in <i>Helicobacter pylori</i> -positive people. <i>The Cochrane Library</i> , 2016, 2016, CD003840.	1.5	112
82	Faecal microbiota transplantation for <i>Clostridium difficile</i> -associated diarrhoea: a systematic review of randomised controlled trials. <i>Medical Journal of Australia</i> , 2017, 207, 166-172.	0.8	109
83	Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 1053-1062.	3.7	109
84	Anxiety and Depression Increase in a Stepwise Manner in Parallel With Multiple FGIDs and Symptom Severity and Frequency. <i>American Journal of Gastroenterology</i> , 2015, 110, 1038-1048.	0.2	108
85	Chronic idiopathic constipation in adults: epidemiology, pathophysiology, diagnosis and clinical management. <i>Medical Journal of Australia</i> , 2018, 209, 86-91.	0.8	108
86	Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 117-131.	3.7	108
87	Adverse events with bismuth salts for <i>Helicobacter pylori</i> eradication: Systematic review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2008, 14, 7361.	1.4	107
88	Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 3-15.	1.9	107
89	Global prevalence of functional constipation according to the Rome criteria: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 638-648.	3.7	105
90	Will the History and Physical Examination Help Establish That Irritable Bowel Syndrome Is Causing This Patient's Lower Gastrointestinal Tract Symptoms?. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 1793.	3.8	98

#	ARTICLE	IF	CITATIONS
91	Clinical and epidemiological differences in functional dyspepsia between the East and the West. <i>Neurogastroenterology and Motility</i> , 2016, 28, 167-174.	1.6	98
92	The overlap of atopy and functional gastrointestinal disorders among 23,471 patients in primary care. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 382-391.	1.9	97
93	Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study. <i>Gut</i> , 2007, 56, 321-327.	6.1	96
94	Efficacy of Pharmacological Therapies for the Treatment of Opioid-Induced Constipation: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2013, 108, 1566-1574.	0.2	92
95	5-Aminosalicylates Prevent Relapse of Crohn's Disease After Surgically Induced Remission: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 413-420.	0.2	91
96	Safety of Adding Oats to a Gluten-Free Diet for Patients With Celiac Disease: Systematic Review and Meta-analysis of Clinical and Observational Studies. <i>Gastroenterology</i> , 2017, 153, 395-409.e3.	0.6	90
97	Characteristics of functional bowel disorder patients: a cross-sectional survey using the Rome III criteria. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 312-321.	1.9	87
98	Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 376-384.e5.	2.4	87
99	Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 831-844.	3.7	87
100	Eradication therapy for peptic ulcer disease in <i>Helicobacter pylori</i> positive patients. , 2006, , CD003840.		85
101	<i>Helicobacter pylori</i> eradication for the prevention of gastric neoplasia. , 2015, , CD005583.		85
102	Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea. <i>Neurogastroenterology and Motility</i> , 2012, 24, 983.	1.6	84
103	<i>Helicobacter pylori</i> test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). <i>BMJ: British Medical Journal</i> , 2008, 336, 651-654.	2.4	81
104	Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With Recurrent <i>Clostridioides difficile</i> Infection Treated With Fecal Microbiota Transplantation or Antibiotics. <i>Annals of Internal Medicine</i> , 2019, 171, 695.	2.0	81
105	Immunologic distribution of an organic anion transport protein in rat liver and kidney. <i>American Journal of Physiology - Renal Physiology</i> , 1996, 271, G231-G238.	1.6	80
106	Gastro-oesophageal reflux is more prevalent in Western dyspeptics: a prospective comparison of British and South-East Asian patients with dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1483-1490.	1.9	80
107	Prevalence of Gastro-Esophageal Reflux-Type Symptoms in Individuals With Irritable Bowel Syndrome in the Community: A Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2012, 107, 1793-1801.	0.2	79
108	Epidemiological, Clinical, and Psychological Characteristics of Individuals with Self-reported Irritable Bowel Syndrome Based on the Rome IV vs Rome III Criteria. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 392-398.e2.	2.4	78



#	ARTICLE	IF	CITATIONS
109	Systematic review: prognostic tests of paracetamol-induced acute liver failure. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 1064-1076.	1.9	76
110	Meta-analysis: coeliac disease and hypertransaminasaemia. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 33-40.	1.9	76
111	Epidemiology and outcomes of gastroparesis, as documented in general practice records, in the United Kingdom. <i>Gut</i> , 2021, 70, 644-653.	6.1	76
112	Prevalence of Uninvestigated Dyspepsia 8 Years After a Large Waterborne Outbreak of Bacterial Dysentery: A Cohort Study. <i>Gastroenterology</i> , 2010, 138, 1727-1736.	0.6	75
113	Effect of Dyspepsia on Survival: A Longitudinal 10-Year Follow-Up Study. <i>American Journal of Gastroenterology</i> , 2012, 107, 912-921.	0.2	74
114	The Short-Form Leeds Dyspepsia Questionnaire validation study. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 477-486.	1.9	73
115	High Prevalence of Idiopathic Bile Acid Diarrhea Among Patients With Diarrhea-Predominant Irritable Bowel Syndrome Based on Rome III Criteria. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1650-1655.e2.	2.4	73
116	Irritable bowel syndrome. <i>BMJ, The</i> , 2012, 345, e5836-e5836.	3.0	72
117	The Rome III Criteria for the Diagnosis of Functional Dyspepsia in Secondary Care Are Not Superior to Previous Definitions. <i>Gastroenterology</i> , 2014, 146, 932-940.e1.	0.6	71
118	Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 449-458.	1.9	70
119	Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 491-503.	1.9	69
120	Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 816-823.	0.6	69
121	Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. <i>Gut</i> , 2022, 71, 1976-1987.	6.1	69
122	Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-Integrin antibodies in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1227-1236.	1.9	68
123	A Community Screening Program for <i>Helicobacter pylori</i> Saves Money: 10-Year Follow-up of a Randomized Controlled Trial. <i>Gastroenterology</i> , 2005, 129, 1910-1917.	0.6	65
124	Who Consults With Dyspepsia? Results from a Longitudinal 10-Yr Follow-Up Study. <i>American Journal of Gastroenterology</i> , 2007, 102, 957-965.	0.2	65
125	Longitudinal impact of IBS-type symptoms on disease activity, healthcare utilization, psychological health, and quality of life in inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2018, 113, 702-712.	0.2	65
126	Prevalence of functional gastrointestinal disorders among consecutive new patient referrals to a gastroenterology clinic. <i>Frontline Gastroenterology</i> , 2014, 5, 266-271.	0.9	64



#	ARTICLE	IF	CITATIONS
127	Initial management strategies for dyspepsia. , 2005, , CD001961.		63
128	Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis. Inflammatory Bowel Diseases, 2019, 25, 1169-1186.	0.9	63
129	Association Between Constipation and Colorectal Cancer: Systematic Review and Meta-Analysis of Observational Studies. American Journal of Gastroenterology, 2013, 108, 894-903.	0.2	62
130	Bidirectional brain-gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis. Gut, 2022, 71, 1773-1780.	6.1	61
131	Irritable Bowel Syndrome and Microscopic Colitis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2016, 14, 659-668.e1.	2.4	60
132	Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2016, 44, 117-126.	1.9	56
133	A Review of the Evidence and Recommendations on Communication Skills and the Patient-Provider Relationship: A Rome Foundation Working Team Report. Gastroenterology, 2021, 161, 1670-1688.e7.	0.6	56
134	British Society of Gastroenterology guidelines on the management of functional dyspepsia. Gut, 2022, 71, 1697-1723.	6.1	54
135	Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia. Alimentary Pharmacology and Therapeutics, 2021, 53, 8-21.	1.9	53
136	Meta-analysis: yield of diagnostic tests for coeliac disease in dyspepsia. Alimentary Pharmacology and Therapeutics, 2009, 30, 28-36.	1.9	52
137	Once-Daily Dosing vs. Conventional Dosing Schedule of Mesalamine and Relapse of Quiescent Ulcerative Colitis: Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2011, 106, 2070-2077.	0.2	52
138	De novo design of covalently constrained mesosize protein scaffolds with unique tertiary structures. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10852-10857.	3.3	52
139	Fluctuation of gastrointestinal symptoms in the community: a 10-year longitudinal follow-up study. Alimentary Pharmacology and Therapeutics, 2008, 28, 1013-1020.	1.9	51
140	Meta-analysis: <i>Helicobacter pylori</i> test and treatment compared with empirical acid suppression for managing dyspepsia. Alimentary Pharmacology and Therapeutics, 2008, 28, 534-544.	1.9	49
141	Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and network meta-analysis. Gut, 2019, 68, 434-444.	6.1	49
142	Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gut, 2021, 70, 1110-1116.	6.1	49
143	The Effect of Dietary Intervention on Irritable Bowel Syndrome: A Systematic Review. Clinical and Translational Gastroenterology, 2015, 6, e107.	1.3	48
144	Diagnosis of IBS: symptoms, symptom-based criteria, biomarkers or 'psychomarkers'?. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 683-691.	8.2	47

#	ARTICLE	IF	CITATIONS
145	Relative Efficacy of Tegaserod in a Systematic Review and Network Meta-analysis of Licensed Therapies for Irritable Bowel Syndrome With Constipation. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1238-1239.e1.	2.4	47
146	Antidepressants in inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 184-192.	8.2	47
147	Systematic review: granulocyte/monocyte adsorptive apheresis for ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1297-1306.	1.9	46
148	Prevalence of Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2021, 161, 1865-1877.	0.6	46
149	Errors in the Conduct of Systematic Reviews of Pharmacological Interventions for Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2010, 105, 280-288.	0.2	45
150	NICE clinical guideline (CG152): the management of Crohn's disease in adults, children and young people. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 195-203.	1.9	45
151	Meta-analysis: the epidemiology of noncardiac chest pain in the community. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 172-180.	1.9	44
152	Efficacy of Topical 5-Aminosalicylates in Preventing Relapse of Quiescent Ulcerative Colitis: A Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 513-519.	2.4	44
153	A Novel Method to Classify and Subgroup Patients With IBS Based on Gastrointestinal Symptoms and Psychological Profiles. <i>American Journal of Gastroenterology</i> , 2021, 116, 372-381.	0.2	43
154	Enhancing Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by Additional History and Limited Diagnostic Evaluation. <i>American Journal of Gastroenterology</i> , 2016, 111, 1446-1454.	0.2	41
155	Efficacy of surgical or endoscopic treatment of idiopathic achalasia: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 30-38.	3.7	41
156	Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 71-75.	0.8	39
157	Development and Validation of a Scoring System to Identify Patients With Microscopic Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1125-1131.	2.4	39
158	Systematic Review and Network Meta-Analysis of Medical Therapies to Prevent Recurrence of Post-Operative Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 693-701.	0.6	39
159	<i>Helicobacter pylori</i> eradication for the prevention of gastric neoplasia. <i>The Cochrane Library</i> , 2020, 7, CD005583.	1.5	39
160	Global prevalence of Barrett's oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: a systematic review and meta-analysis. <i>Gut</i> , 2021, 70, 456-463.	6.1	39
161	Cyclic vomiting syndrome is a prevalent and under-recognized condition in the gastroenterology outpatient clinic. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13174.	1.6	37
162	Low-dose imipramine for refractory functional dyspepsia: a randomised, double-blind, placebo-controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 837-844.	3.7	37

#	ARTICLE	IF	CITATIONS
163	Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 110-120.	1.9	37
164	Rome IV criteria for FGIDs – an improvement or more of the same?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 501-502.	8.2	36
165	The relationship between different information sources and disease-related patient knowledge and anxiety in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 63-74.	1.9	36
166	Effectiveness of management strategies for uninvestigated dyspepsia: systematic review and network meta-analysis. <i>BMJ</i> , 2019, 367, l6483.	3.0	36
167	Anxiety But Not Depression Predicts Poor Outcomes in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1255-1261.	0.9	36
168	Mycophenolate mofetil therapy for refractory inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1488-1492.	0.9	35
169	Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 700-707.	0.6	35
170	Current Guidelines for Dyspepsia Management. <i>Digestive Diseases</i> , 2008, 26, 225-230.	0.8	34
171	Common mental disorders in irritable bowel syndrome: pathophysiology, management, and considerations for future randomised controlled trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 401-410.	3.7	34
172	Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2021, 116, 362-371.	0.2	34
173	Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. <i>Digestive and Liver Disease</i> , 2015, 47, 356-364.	0.4	33
174	Pharmacotherapy for Irritable Bowel Syndrome. <i>Journal of Clinical Medicine</i> , 2017, 6, 101.	1.0	33
175	Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1357-1363.	1.9	32
176	Effect of sibling number in the household and birth order on prevalence of <i>Helicobacter pylori</i> : a cross-sectional study. <i>International Journal of Epidemiology</i> , 2007, 36, 1327-1333.	0.9	31
177	IBS-like symptoms in patients with ulcerative colitis. <i>Clinical and Experimental Gastroenterology</i> , 2015, 8, 101.	1.0	31
178	Ipilimumab-induced colitis: experience from a tertiary referral center. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 457-462.	1.4	31
179	Efficacy of <i>Helicobacter pylori</i> eradication therapy for functional dyspepsia: updated systematic review and meta-analysis. <i>Gut</i> , 2022, 71, 1967-1975.	6.1	31
180	Increased prevalence of autoimmune diseases in functional gastrointestinal disorders: case-control study of 23,471 primary care patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 827-834.	1.9	30

#	ARTICLE	IF	CITATIONS
181	Beliefs about management of irritable bowel syndrome in primary care: cross-sectional survey in one locality. <i>Primary Health Care Research and Development</i> , 2015, 16, 263-269.	0.5	30
182	Anxiety-related factors associated with symptom severity in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13872.	1.6	30
183	Impact of Rome IV irritable bowel syndrome on work and activities of daily living. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 844-856.	1.9	30
184	Prevalence of Dyspepsia in Individuals With Gastroesophageal Reflux-Related Type Symptoms in the Community: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 39-48.e1.	2.4	29
185	Systematic review with meta-analysis: global prevalence of uninvestigated dyspepsia according to the Rome criteria. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 762-773.	1.9	29
186	Evaluation of a faecal calprotectin care pathway for use in primary care. <i>Primary Health Care Research and Development</i> , 2016, 17, 428-436.	0.5	28
187	Functional Dyspepsia. <i>New England Journal of Medicine</i> , 2016, 374, 895-896.	13.9	28
188	Mycophenolate mofetil in refractory inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 1365-1369.	1.9	26
189	Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents. <i>Therapeutic Advances in Gastroenterology</i> , 2011, 4, 115-127.	1.4	26
190	Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 431-442.	1.4	26
191	Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1184-1196.	0.6	26
192	A specific microbiota signature is associated to various degrees of ulcerative colitis as assessed by a machine learning approach. <i>Gut Microbes</i> , 2022, 14, 2028366.	4.3	26
193	Long-term Efficacy and Safety of Azathioprine in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 191-197.	0.6	25
194	Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches. <i>Handbook of Experimental Pharmacology</i> , 2016, 239, 75-113.	0.9	25
195	Best management of irritable bowel syndrome. <i>Frontline Gastroenterology</i> , 2021, 12, 303-315.	0.9	25
196	Chronic constipation in adults: Contemporary perspectives and clinical challenges. 1: Epidemiology, diagnosis, clinical associations, pathophysiology and investigation. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14050.	1.6	25
197	Advances in pathophysiology, diagnosis and treatment. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 76-78.	8.2	24
198	Placebo Response Rate in Clinical Trials of Fistulizing Crohn's Disease: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1981-1990.	2.4	24

#	ARTICLE	IF	CITATIONS
199	Impact of Psychological Comorbidity on the Prognosis of Irritable Bowel Syndrome. American Journal of Gastroenterology, 2021, 116, 1485-1494.	0.2	24
200	Efficacy of infliximab in acute severe ulcerative colitis: A single-centre experience. World Journal of Gastroenterology, 2013, 19, 1091.	1.4	24
201	Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience. Journal of Crohn's and Colitis, 2011, 5, 324-331.	0.6	23
202	Chemoprevention for gastric cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 581-592.	1.0	23
203	The natural history of gastroesophageal reflux symptoms in the community and its effects on survival: a longitudinal 10-year follow-up study. Alimentary Pharmacology and Therapeutics, 2013, 37, 323-331.	1.9	23
204	Insights into the evaluation and management of dyspepsia: recent developments and new guidelines. Therapeutic Advances in Gastroenterology, 2018, 11, 175628481880559.	1.4	23
205	Clinical Application of Dietary Therapies in Irritable Bowel Syndrome. Journal of Gastrointestinal and Liver Diseases, 2019, 27, 307-316.	0.5	23
206	Macroscopic findings, incidence and characteristics of microscopic colitis in a large cohort of patients from the United Kingdom. Scandinavian Journal of Gastroenterology, 2017, 52, 1-7.	0.6	22
207	Acupuncture and related therapies for treating irritable bowel syndrome: overview of systematic reviews and network meta-analysis. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481882043.	1.4	22
208	Natural History and Disease Impact of Rome IV Vs Rome III Irritable Bowel Syndrome: A Longitudinal Follow-Up Study. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	22
209	Placebo Response Rates in Trials of Licensed Drugs for Irritable Bowel Syndrome With Constipation or Diarrhea: Meta-analysis. Clinical Gastroenterology and Hepatology, 2022, 20, e923-e944.	2.4	22
210	The Effect of Antidepressants on the Course of Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-11.	0.8	21
211	No Significant Association Between the Fecal Microbiome and the Presence of Irritable Bowel Syndrome-type Symptoms in Patients with Quiescent Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 1597-1605.	0.9	20
212	AGA Clinical Practice Update on Management of Chronic Gastrointestinal Pain in Disorders of Gut-Brain Interaction: Expert Review. Clinical Gastroenterology and Hepatology, 2021, 19, 2481-2488.e1.	2.4	20
213	Efficacy and tolerability of methotrexate therapy for refractory Crohn's disease: a large single-centre experience. Alimentary Pharmacology and Therapeutics, 2012, 35, 284-291.	1.9	19
214	Longitudinal follow-up study: effect of psychological comorbidity on the prognosis of inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2021, 54, 441-450.	1.9	19
215	Redundant Data in the Meta-analysis on <i>Helicobacter pylori</i> Eradication. Annals of Internal Medicine, 2009, 151, 513.	2.0	18
216	Dyspepsia. Current Opinion in Gastroenterology, 2013, 29, 662-668.	1.0	18

#	ARTICLE	IF	CITATIONS
217	Functional dyspepsia. <i>Current Opinion in Gastroenterology</i> , 2015, Publish Ahead of Print, 492-8.	1.0	18
218	No increase in prevalence of somatization in functional <i>vs</i> organic dyspepsia: a cross-sectional survey. <i>Neurogastroenterology and Motility</i> , 2015, 27, 1024-1031.	1.6	18
219	Factors affecting clinical decision-making in inflammatory bowel disease and the role of point-of-care calprotectin. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 1756283X1774473.	1.4	18
220	Incidental focal colonic lesions found on <sup>18</sup>Fluorodeoxyglucose positron emission tomography/computed tomography scan: further support for a national guideline on definitive management. <i>Colorectal Disease</i> , 2012, 14, e56-63.	0.7	17
221	Cyclic vomiting syndrome: a case series and review of the literature. <i>Frontline Gastroenterology</i> , 2018, 9, 2-9.	0.9	17
222	Chronic constipation in adults: Contemporary perspectives and clinical challenges. 2: Conservative, behavioural, medical and surgical treatment. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14070.	1.6	17
223	Overlap of Rome IV Irritable Bowel Syndrome and Functional Dyspepsia and Effect on Natural History: A Longitudinal Follow-Up Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e89-e101.	2.4	17
224	Longitudinal follow-up of a novel classification system for irritable bowel syndrome: natural history and prognostic value. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1126-1137.	1.9	17
225	Functional gastrointestinal disorders in inflammatory bowel disease: Time for a paradigm shift?. <i>World Journal of Gastroenterology</i> , 2020, 26, 3712-3719.	1.4	17
226	Relative Contribution of Disease Activity and Psychological Health to Prognosis of Inflammatory Bowel Disease During 6.5 Years of Longitudinal Follow-Up. <i>Gastroenterology</i> , 2022, 163, 190-203.e5.	0.6	17
227	Symptom-Based Diagnostic Criteria for Irritable Bowel Syndrome: the More Things Change, the More They Stay the Same. <i>Gastroenterology Clinics of North America</i> , 2011, 40, 87-103.	1.0	16
228	Lack of Utility of Symptoms and Signs at First Presentation as Predictors of Inflammatory Bowel Disease in Secondary Care. <i>American Journal of Gastroenterology</i> , 2015, 110, 716-724.	0.2	16
229	Validation and modification of a diagnostic scoring system to predict microscopic colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1206-1212.	0.6	16
230	Fatigue in Inflammatory Bowel Disease Reflects Mood and Symptom-Reporting Behavior Rather Than Biochemical Activity or Anemia. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1165-1167.	2.4	16
231	Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1311-1319.	1.9	16
232	Recent developments in gastroenterology. <i>BMJ: British Medical Journal</i> , 2002, 325, 1399-1402.	2.4	15
233	Laxatives for chronic constipation in adults. <i>BMJ, The</i> , 2012, 345, e6168-e6168.	3.0	15
234	Bathyal demersal fishes of Charlie-Gibbs Fracture Zone region (49°54'N) of the Mid-Atlantic Ridge: II. Baited camera lander observations. <i>Deep-Sea Research Part II: Topical Studies in Oceanography</i> , 2013, 98, 397-406.	0.6	15



#	ARTICLE	IF	CITATIONS
235	Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 2083-2088.	0.9	15
236	Systematic review and network meta-analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 98-108.	1.9	15
237	Irritable Bowel Syndrome-Type Symptoms Are Associated With Psychological Comorbidity, Reduced Quality of Life, and Health Care Use in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2017, 153, 324-325.	0.6	14
238	Quality of Care and the Irritable Bowel Syndrome: Is Now the Time to Set Standards?. <i>American Journal of Gastroenterology</i> , 2018, 113, 167-169.	0.2	14
239	Rational investigations in irritable bowel syndrome. <i>Frontline Gastroenterology</i> , 2020, 11, 140-147.	0.9	14
240	Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 375-383.	0.6	13
241	Postoperative prophylaxis in Crohn's disease after intestinal resection: a retrospective analysis. <i>Frontline Gastroenterology</i> , 2017, 8, 203-209.	0.9	13
242	Review: Prevention and management of gastric cancer. <i>Helicobacter</i> , 2020, 25, e12740.	1.6	13
243	Constipation Predominant Irritable Bowel Syndrome and Functional Constipation Are Not Discrete Disorders: A Machine Learning Approach. <i>American Journal of Gastroenterology</i> , 2021, 116, 142-151.	0.2	13
244	Association of proton-pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta-analyses of cohort studies and randomised controlled trials. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1551-1566.	1.1	13
245	Effect of gastroesophageal reflux symptoms on the risk of Barrett's esophagus: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1507-1516.	1.4	13
246	Dyspepsia. <i>BMJ</i> , The, 2013, 347, f5059-f5059.	3.0	12
247	Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial. <i>Trials</i> , 2019, 20, 517.	0.7	12
248	Development of a real-time patient-reported outcome measure for symptom assessment in patients with functional dyspepsia using the experience sampling method. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13496.	1.6	12
249	Effect of ACE inhibitors and angiotensin II receptor blockers on disease outcomes in inflammatory bowel disease. <i>Gut</i> , 2021, 70, 218.2-219.	6.1	12
250	Systematic review with meta-analysis: risk factors for Barrett's oesophagus in individuals with gastroesophageal reflux symptoms. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 968-976.	1.9	12
251	Clinical trial: knowledge of negative <i>Helicobacter pylori</i> status reduces subsequent dyspepsia-related resource use. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 1267-1275.	1.9	11
252	Initial management of dyspepsia in primary care: an evidence-based approach. <i>British Journal of General Practice</i> , 2013, 63, 498-499.	0.7	11



#	ARTICLE	IF	CITATIONS
253	Poor predictive value of lower gastrointestinal alarm features in the diagnosis of colorectal cancer in 1981 patients in secondary care. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 91-99.	1.9	11
254	Prevalence of, and predictors of, bile acid diarrhea in outpatients with chronic diarrhea: A follow-up study. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13666.	1.6	11
255	Randomized controlled trial: a pilot study of a psychoeducational intervention for fatigue in patients with quiescent inflammatory bowel disease. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231983843.	1.1	11
256	Systematic review with meta-analysis: association of <i>Helicobacter pylori</i> infection with gastroesophageal reflux and its complications. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 988-998.	1.9	11
257	Managing dyspepsia. <i>Current Gastroenterology Reports</i> , 2009, 11, 288-294.	1.1	10
258	Eradicating <i>Helicobacter Pylori</i> in Functional Dyspepsia. <i>Gastroenterology</i> , 2012, 142, 1613-1614.	0.6	10
259	Derivation and validation of a diagnostic test for irritable bowel syndrome using latent class analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 824-832.	1.9	10
260	Ciclosporin or Infliximab as Rescue Therapy in Acute Glucocorticosteroid-Refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 733-741.	0.6	10
261	Balancing risks and benefits of prucalopride for the treatment of chronic constipation in Asians. <i>Neurogastroenterology and Motility</i> , 2013, 25, 89-89.	1.6	9
262	The possible risks of proton pump inhibitors. <i>Medical Journal of Australia</i> , 2016, 205, 292-293.	0.8	9
263	The Efficacy of Probiotics in the Therapy of Irritable Bowel Syndrome (IBS). <i>American Journal of Gastroenterology</i> , 2008, 103, S481.	0.2	9
264	Long-Term Impact of <i>Helicobacter pylori</i> Eradication Therapy on Gastric Cancer Incidence and Mortality in Healthy Infected Individuals: A Meta-Analysis Beyond 10 Years of Follow-Up. <i>Gastroenterology</i> , 2022, 163, 754-756.e1.	0.6	9
265	Efficacy of Probiotics in Irritable Bowel Syndrome: A Meta-Analysis of Randomized, Controlled Trials. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 1805.	0.7	8
266	Whom should we "test and treat" for <i>Helicobacter pylori</i> ?. <i>BMJ, The</i> , 2014, 348, g3320-g3320.	3.0	8
267	The Importance of Smoking Cessation in Improving Disease Course in Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, 1198.	0.2	8
268	General practitioners' perceptions of irritable bowel syndrome: a Q-methodological study. <i>Family Practice</i> , 2018, 35, 74-79.	0.8	8
269	High prevalence of irritable bowel syndrome-type symptoms in microscopic colitis: implications for treatment. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481878360.	1.4	8
270	Derivation and validation of a novel method to subgroup patients with functional dyspepsia: beyond upper gastrointestinal symptoms. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 253-264.	1.9	8

#	ARTICLE	IF	CITATIONS
271	Latent class analysis does not support the existence of Rome IV functional bowel disorders as discrete entities. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14391.	1.6	8
272	The American College of Gastroenterology Irritable Bowel Syndrome Monograph: Translating Systematic Review Data to Clinical Practice. <i>Gastroenterology</i> , 2010, 138, 789-791.	0.6	7
273	Efficacy of Traditional Chinese Medicine in Functional Constipation. <i>American Journal of Gastroenterology</i> , 2011, 106, 1003.	0.2	7
274	Linacotide: new mechanisms and new promise for treatment in constipation and irritable bowel syndrome. <i>Therapeutic Advances in Chronic Disease</i> , 2013, 4, 268-276.	1.1	7
275	Screening for bile acid diarrhoea in suspected irritable bowel syndrome. <i>Gut</i> , 2015, 64, 851.1-851.	6.1	7
276	Stool as a treatment for IBS: more questions than answers?. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 2-3.	3.7	7
277	Fatigue and its associated factors in microscopic colitis. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481879959.	1.4	7
278	Commentary: estimating the prevalence of IBS globally—past, present and future. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 198-199.	1.9	7
279	Letter: faecal microbiota transplantation for irritable bowel syndrome—room for improvement. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 923-924.	1.9	7
280	Peppermint Oil in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2020, 159, 395-396.	0.6	7
281	Acceptability of a “treat to target” approach in inflammatory bowel disease to patients in clinical remission. <i>Frontline Gastroenterology</i> , 2021, 12, 30-38.	0.9	7
282	Psychometric evaluation of an experience sampling method—based patient-reported outcome measure in functional dyspepsia. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14136.	1.6	7
283	The impact of the coronavirus (COVID-19) pandemic on individuals with gastrointestinal disorders: A protocol of an international collaborative study. <i>Journal of Psychosomatic Research</i> , 2021, 148, 110561.	1.2	7
284	Irritable bowel syndrome. <i>Clinical Evidence</i> , 2012, 2012, .	0.2	7
285	VSL#3 and Remission in Active Ulcerative Colitis: Larger Studies Required. <i>American Journal of Gastroenterology</i> , 2011, 106, 547.	0.2	6
286	Acupuncture for Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2012, 143, 1683-1684.	0.6	6
287	Use of Biomarkers in Irritable Bowel Syndrome: To Predict the Future, Look at the Past. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e116.	1.3	6
288	Symbiotics in irritable bowel syndrome — better than probiotics alone?. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2015, 18, 485-489.	1.3	6

#	ARTICLE	IF	CITATIONS
289	Ongoing Symptoms in Ulcerative Colitis Patients in Remission. <i>Inflammatory Bowel Diseases</i> , 2017, 23, E4-E5.	0.9	6
290	A Bidirectional Relationship Between Symptom Reporting and Perceived Stress, But Not Disease Activity, in Inflammatory Bowel Disease: More Questions Than Answers?. <i>Gastroenterology</i> , 2017, 153, 1444-1445.	0.6	6
291	Prevalence and impact of Rome IV versus Rome III irritable bowel syndrome in patients with inflammatory bowel disease. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14256.	1.6	6
292	Does <i>Helicobacter pylori</i> really cause duodenal ulcers? Yes. <i>BMJ: British Medical Journal</i> , 2009, 339, b2784-b2784.	2.4	6
293	Adverse events in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: Systematic review and meta-analysis. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14279.	1.6	6
294	Assessing the Impact of Changes to the Rome IV Criteria for Clinical Practice in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2022, 162, 1752-1754.e1.	0.6	6
295	Evidence-based management of ulcerative colitis. <i>Minerva Gastroenterologica E Dietologica</i> , 2012, 58, 87-99.	2.2	6
296	Probiotics in irritable bowel syndrome: underachievers or underpowered?. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 922-923.	1.9	5
297	Utility of Fecal Calprotectin in Differentiating Active Inflammatory Bowel Disease From Coexistent Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2011, 106, 166.	0.2	5
298	Direction of the brain-gut pathway in functional gastrointestinal disorders. <i>Gut</i> , 2012, 61, 1368.1-1368.	6.1	5
299	Efficacy of granulocyte/monocyte apheresis for moderate to severe Crohn's disease. <i>Gut</i> , 2013, 62, 653.1-653.	6.1	5
300	Functional Bowel Symptoms in Quiescent Inflammatory Bowel Disease: More Than Just Irritable Bowel Syndrome?. <i>Gastroenterology</i> , 2014, 147, 1176-1177.	0.6	5
301	Masquerading Gastrointestinal Polyps: Air on the Side of Caution?. <i>Gastroenterology</i> , 2014, 146, e9-e10.	0.6	5
302	Reducing the Need for Random Colonic Biopsies in Patients With Diarrhea. <i>American Journal of Gastroenterology</i> , 2015, 110, 351-352.	0.2	5
303	Psychological Comorbidity and Inflammatory Bowel Disease Activity: Cause or Effect?. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1061-1062.	2.4	5
304	Cyclic Vomiting Syndrome: Randomized Controlled Trials Are also Needed in Adults. <i>American Journal of Gastroenterology</i> , 2017, 112, 1752-1753.	0.2	5
305	The Glasgow Prognostic Score at the Time of Palliative Esophageal Stent Insertion is a Predictive Factor of 30-Day Mortality and Overall Survival. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 223-228.	1.1	5
306	Sarcopenia, severe anxiety and increased C-reactive protein are associated with severe fatigue in patients with inflammatory bowel diseases. <i>Scientific Reports</i> , 2021, 11, 15251.	1.6	5

#	ARTICLE	IF	CITATIONS
307	Treatment of chronic gastro-oesophageal reflux disease. <i>BMJ: British Medical Journal</i> , 2009, 339, b2481-b2481.	2.4	4
308	10â€biomarker algorithm to identify irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 95-96.	1.9	4
309	Applicability of the reported prevalence of bile salt malabsorption in irritable bowel. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 161-162.	1.9	4
310	Effect of oral zinc in hepatic encephalopathy remains unclear. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1405-1406.	1.9	4
311	Overlap Among the Functional Gastrointestinal Disorders. <i>American Journal of Gastroenterology</i> , 2010, 105, 2512.	0.2	4
312	In irritable bowel syndrome, antispasmodics and antidepressants improve abdominal pain and global assessment and symptom scores, but there is no evidence for the effectiveness of bulking agents. <i>Evidence-Based Medicine</i> , 2012, 17, 114-115.	0.6	4
313	Poor Correlation Between Patient-reported and Endoscopic Components of the Mayo Score in Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 1037-1039.	0.6	4
314	Letter: causes of fatigue in inflammatory bowel disease remain uncertain. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 762-763.	1.9	4
315	Making a positive diagnosis of irritable bowel syndrome. <i>British Journal of General Practice</i> , 2017, 67, 580-581.	0.7	4
316	Efficacy of glutamine in postinfection IBS. <i>Gut</i> , 2019, 68, 1905-1906.	6.1	4
317	Characteristics of, and natural history among, individuals with Rome IV functional bowel disorders. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14268.	1.6	4
318	Management of irritable bowel syndrome. <i>Minerva Gastroenterologica E Dietologica</i> , 2009, 55, 273-87.	2.2	4
319	Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The Tj ETQq1 1 0.784314 rgBT /Overloc Trials, 2022, 23, .	0.7	4
320	Is the Benefit of Granulocyte Monocyte Adsorptive Apheresis in Ulcerative Colitis Overstated?. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1803-1804.	1.1	3
321	Alverine citrate, simeticone, and Rome III irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 767-768.	1.9	3
322	Renzapride in IBS: is efficacy in the eye of the beholder?. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 113-114.	1.9	3
323	Infliximab rescue therapy in ulcerative colitis, and the effect on subsequent colectomy rates. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1294-1295.	1.9	3
324	Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease. <i>Gut</i> , 2010, 59, 1731-1732.	6.1	3

#	ARTICLE	IF	CITATIONS
325	ROME III Criteria for Functional Gastrointestinal Disorders: Too Much Overlap to Be Useful?. <i>Gastroenterology</i> , 2011, 140, S-725-S-726.	0.6	3
326	Death Knell for Placebo-Controlled Trials in Chronic Idiopathic Constipation?. <i>Gastroenterology</i> , 2013, 145, 897-898.	0.6	3
327	Polyethylene Glycol in Constipation-Predominant Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2014, 109, 135.	0.2	3
328	Do Lay People Accept a Positive Diagnosis of Irritable Bowel Syndrome?. <i>Gastroenterology</i> , 2015, 149, 252-253.	0.6	3
329	Imipramine for Treatment of Esophageal Hypersensitivity and Functional Heartburn. <i>American Journal of Gastroenterology</i> , 2016, 111, 1358.	0.2	3
330	Efficacy of mesalazine in IBS. <i>Gut</i> , 2016, 65, 187.1-188.	6.1	3
331	Minimal differences in prevalence and spectrum of organic disease at upper gastrointestinal endoscopy between selected secondary care patients with symptoms of gastro-oesophageal reflux or dyspepsia. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 396-402.	0.6	3
332	Use of Probiotics in Hospitalized Adults to Prevent Clostridium difficile Infection: DownGRADE the Quality of Evidence?. <i>Gastroenterology</i> , 2017, 153, 1451-1452.	0.6	3
333	Multiple myeloma presenting in association with gastric phytobezoar. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 1493-1495.	0.2	3
334	Possible Redundant Data in the Network Meta-analysis of Pharmacological Therapies for Opioid-Induced Constipation. <i>Journal of Pain and Symptom Management</i> , 2018, 55, e8-e9.	0.6	3
335	Mizagliflozin for the Treatment of Functional Constipation: Are New Drugs Better?. <i>Gastroenterology</i> , 2019, 156, 818-820.	0.6	3
336	Healthy Mind, Healthy Body: Chronic Depression May Predate the Development of Inflammatory Bowel Disease by up to 9 Years. <i>Gastroenterology</i> , 2021, 160, 2611-2613.	0.6	3
337	Irritable bowel syndrome: a spotlight on future research needs. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 419-422.	3.7	3
338	Should we step up or step down in the treatment of new onset dyspepsia in primary care?. <i>Polish Archives of Internal Medicine</i> , 2009, 119, 391-396.	0.3	3
339	Generalized anxiety disorder and irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 1087-1088.	1.9	2
340	Dyspepsia and irritable bowel syndrome: mutually exclusive conditions?. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 612-613.	1.9	2
341	Power of Selective Serotonin Reuptake Inhibitors in Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 313-314.	2.4	2
342	Breath testing and antibiotics for possible bacterial overgrowth in irritable bowel syndrome. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 855-857.	2.0	2

#	ARTICLE	IF	CITATIONS
343	Efficacy of antidepressants in irritable bowel syndrome: an updated systematic review and meta-analysis controlling for depression. <i>Gut</i> , 2011, 60, A154-A155.	6.1	2
344	Defining a responder in treatment trials for chronic idiopathic constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 285-286.	1.9	2
345	Is otilonium bromide globally effective in irritable bowel syndrome?. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1034-1035.	1.9	2
346	First-line Eradication Therapy for <i>Helicobacter pylori</i> : Time for a Change?. <i>Gastroenterology</i> , 2013, 144, 652-653.	0.6	2
347	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 102-103.	2.4	2
348	Letter: bile acid diarrhoea is not a rare cause of diarrhoea in secondary care. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 216-216.	1.9	2
349	Rates of upper gastrointestinal endoscopy and gastro-oesophageal malignancy outcomes. <i>Gut</i> , 2014, 63, 703.1-703.	6.1	2
350	Letter: is there a bi-directional relationship between depression and IBD?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 213-213.	1.9	2
351	PTU-075...Systematic Review And Meta-analysis: Sensitivity And Specificity Of Tc-99m Hmpao Labeled White Cell Scintigraphy In The Diagnosis Of Active Inflammatory Bowel Disease. <i>Gut</i> , 2014, 63, A71.2-A71.	6.1	2
352	Irritable bowel syndrome and somatization. <i>Neurogastroenterology and Motility</i> , 2015, 27, 740-740.	1.6	2
353	Combining Biomarkers in Irritable Bowel Syndrome: A Forward Step Toward Making a Positive Diagnosis and Directing Therapy?. <i>Gastroenterology</i> , 2015, 148, 1471-1473.	0.6	2
354	Aetiopathogenesis of functional dyspepsia. <i>Gut</i> , 2015, 64, 1182-1183.	6.1	2
355	Defining the Relationship Between Clinical and Biochemical Disease Activity Indices and Perceived Stress in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2015, 149, 1632-1634.	0.6	2
356	Central Pain Processing in Irritable Bowel Syndrome Is modulated By Mood: A Mechanism for the Beneficial Effects of Antidepressants?. <i>Gastroenterology</i> , 2015, 148, 247-248.	0.6	2
357	Editorial: Using Patient-Reported Outcome Measures in Gastroenterology: PROMISed Land or Road to Nowhere?. <i>American Journal of Gastroenterology</i> , 2016, 111, 1557-1558.	0.2	2
358	Depression Is Associated With Subjective Measures of Crohn's Disease Activity During Longitudinal Follow-up. <i>Gastroenterology</i> , 2016, 151, 762-763.	0.6	2
359	Reactive Versus Proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease Patients Treated With Infliximab: A Self-Fulfilling Prophecy. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1638.	2.4	2
360	Editorial: subgroups in irritable bowel syndrome – more than just diarrhoea and constipation?. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 697-697.	1.9	2

#	ARTICLE	IF	CITATIONS
361	Probiotics for Treating Irritable Bowel Syndrome: Are Bugs the Best Drugs?. <i>Gastroenterology</i> , 2018, 155, 2019-2021.	0.6	2
362	Depression, Antidepressants, and Inflammatory Bowel Disease: Implications for Future Models of Care. <i>Gastroenterology</i> , 2019, 156, 2345-2347.	0.6	2
363	Editorial: minesapride for irritable bowel syndrome with constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 713-714.	1.9	2
364	Efficacy of Eluxadoline in Irritable Bowel Syndrome With Diarrhea. <i>American Journal of Gastroenterology</i> , 2020, 115, 483-484.	0.2	2
365	Use of Lactulose Breath Tests to Predict Response to Rifaximin in Irritable Bowel Syndrome With Diarrhea: The Positives and Negatives. <i>American Journal of Gastroenterology</i> , 2020, 115, 955-956.	0.2	2
366	061â€¦Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. , 2021, , .		2
367	Global Prevalence of Chronic Idiopathic Constipation According to the Rome Criteria: Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
368	Utility of Diagnostic Tests for Celiac Disease in Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2008, 103, S463.	0.2	2
369	Efficacy of Antidepressants in Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2008, 103, S476-S477.	0.2	2
370	Biochemical Tests for Bile Acid Diarrhea: Real-World Studies Required. <i>American Journal of Gastroenterology</i> , 2021, 116, 833-834.	0.2	2
371	<i>Helicobacter pylori</i> infection. <i>Clinical Evidence</i> , 2009, 2009, .	0.2	2
372	Irritable bowel syndrome: dietary interventions. <i>Clinical Evidence</i> , 2015, 2015, .	0.2	2
373	<i>Helicobacter pylori</i> eradication: gastric cancer prevention. <i>Clinical Evidence</i> , 2015, 2015, .	0.2	2
374	Should we step-up or step-down in the treatment of new-onset dyspepsia in primary care?. , 2009, 119, 391-6.		2
375	Image of the month. <i>Gastroenterology</i> , 2002, 122, 1720.	0.6	1
376	Image of the Month. <i>Gastroenterology</i> , 2005, 129, 785.	0.6	1
377	Testing for Celiac Disease in Patients With Symptoms of Irritable Bowel Syndromeâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1126.	3.8	1
378	Reporting of relapse rates in a trial of mesalazine for ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1205-1206.	1.9	1



#	ARTICLE	IF	CITATIONS
379	Medical or Surgical Therapy for Gastroesophageal Reflux Disease?. <i>Gastroenterology</i> , 2011, 141, 1938-1939.	0.6	1
380	Efficacy of prucalopride in the treatment of chronic idiopathic constipation: systematic review and meta-analysis. <i>Gut</i> , 2011, 60, A154-A154.	6.1	1
381	Do dried plums really help constipation?. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 1258-1259.	1.9	1
382	Losses to Follow-Up Limit Conclusions Regarding the Efficacy of Branched-Chain Amino Acids in Patients With Hepatic Encephalopathy. <i>American Journal of Gastroenterology</i> , 2011, 106, 1718.	0.2	1
383	Letter: the effects of overlapping symptoms on the response to <sc>PPI</sc> therapy in <sc>GERD</sc>. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 207-207.	1.9	1
384	Response to Neis et al.. <i>American Journal of Gastroenterology</i> , 2013, 108, 1930.	0.2	1
385	Letter: effects of iron therapy after non-variceal acute upper gastrointestinal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 346-346.	1.9	1
386	The Fall and Rise of 5-Hydroxytryptamine Receptor Antagonists in Irritable Bowel Syndrome With Diarrhea. <i>Gastroenterology</i> , 2014, 147, 527-528.	0.6	1
387	Diagnosing Irritable Bowel Syndrome With a Combination of Biomarkers and "Psychomarkers". <i>Gastroenterology</i> , 2014, 146, 1418-1420.	0.6	1
388	Letter: therapeutic trial is more informative than SeHCAT to diagnose bile acid malabsorption - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 781-781.	1.9	1
389	Lubiprostone Is Effective in Treating Functional Bowel Disease With Constipation. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1378-1379.	2.4	1
390	Ondansetron and irritable bowel syndrome. <i>Gut</i> , 2015, 64, 1181.1-1181.	6.1	1
391	VSL#3 in Postoperative Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1855.	2.4	1
392	Efficacy of hypnotherapy in one thousand patients with irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1222-1223.	1.9	1
393	Screening for Celiac Disease in Individuals With Symptoms Suggestive of Irritable Bowel Syndrome: Still a Worthwhile Exercise. <i>Gastroenterology</i> , 2016, 151, 368-370.	0.6	1
394	PTU-127...Efficacy of Linaclotide in Constipation-Predominant Irritable Bowel Syndrome in Routine Clinical Practice: A Multicentre Experience. <i>Gut</i> , 2016, 65, A119-A119.	6.1	1
395	Letter: smoking as a modifiable risk factor for a complicated course in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 440-440.	1.9	1
396	Editorial: challenging established perceptions of brain-gut interactions in functional gastrointestinal disorders - "brain-gut, gut-brain, or both?". <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 899-900.	1.9	1

#	ARTICLE	IF	CITATIONS
397	Simple Clinical Colitis Activity Index: Accurate Assessment of Inflammatory Burden or Reflection of Low Mood and Somatoform Behavior?. <i>American Journal of Gastroenterology</i> , 2016, 111, 900-901.	0.2	1
398	Editorial: volatile organic compounds in irritable bowel syndrome - technology for an accurate and reliable point-of-care test?. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 563-564.	1.9	1
399	Editorial: mesalazine to prevent recurrent acute diverticulitis—the final nail in the coffin. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 461-462.	1.9	1
400	Defining the relationship between depression and disease activity in IBD using clinical disease activity indices: merit or misnomer?. <i>American Journal of Gastroenterology</i> , 2018, 113, 773-774.	0.2	1
401	Histologic Criteria to Define Irritable Bowel Syndrome: Within the Realms of Possibility?. <i>Gastroenterology</i> , 2018, 154, 1539-1541.	0.6	1
402	Intending to Treat Patients With Irritable Bowel Syndrome With Cognitive Behavioral Therapy. <i>Gastroenterology</i> , 2018, 155, 2024.	0.6	1
403	Young GI angle: How to approach evidence-based medicine. <i>United European Gastroenterology Journal</i> , 2018, 6, 794-795.	1.6	1
404	Utility of the Oral Capsaicin Test in Diagnosing Functional Dyspepsia. <i>American Journal of Gastroenterology</i> , 2018, 113, 1257-1258.	0.2	1
405	Assessing the efficacy of peripherally acting $\mu$ -opioid receptor antagonists (PAMORAs) in the treatment of opioid-induced constipation: authors reply. <i>Gut</i> , 2019, 68, 1530-1531.	6.1	1
406	Editorial: understanding differences in patient response to ondansetron in irritable bowel syndrome with diarrhoea—are we any closer?. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 825-826.	1.9	1
407	Functional Gastrointestinal Symptoms in Inflammatory Bowel Disease: Rising to the Challenge. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 572-573.	2.4	1
408	Letter: meta-analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1254-1255.	1.9	1
409	Relative Efficacy of Naloxegol and Polyethylene Glycol 3350 in Opioid-Induced Constipation. <i>American Journal of Gastroenterology</i> , 2019, 114, 1694-1694.	0.2	1
410	Predictors of Dyspareunia Among Female Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1000-1001.	2.4	1
411	How effective are antibiotics for the treatment of irritable bowel syndrome?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2195-2197.	0.9	1
412	Faecal incontinence is not rare in irritable bowel syndrome. <i>Frontline Gastroenterology</i> , 2020, 11, 494.2-496.	0.9	1
413	Practical plus personal: a refreshing approach to careers advice by the British Society of Gastroenterology Taster Course. <i>Frontline Gastroenterology</i> , 2020, 11, 494.1-494.	0.9	1
414	Predicting Response to Rifaximin in Irritable Bowel Syndrome with Diarrhea: Is the Answer Blowing in the Wind?. <i>Gastroenterology</i> , 2020, 158, 1508-1510.	0.6	1

#	ARTICLE	IF	CITATIONS
415	Polyethylene glycol-based laxatives for chronic constipation â€“ Authors' reply. The Lancet Gastroenterology and Hepatology, 2020, 5, 110-111.	3.7	1
416	Satiation or satiety? More than mere semantics â€“ Authors' reply. Lancet, The, 2021, 397, 1061.	6.3	1
417	Reply. Clinical Gastroenterology and Hepatology, 2021, 19, 1737-1738.	2.4	1
418	Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results. Inflammatory Intestinal Diseases, 2021, 6, 132-139.	0.8	1
419	Bran's deleterious effects: much ado about nothing. BMJ: British Medical Journal, 2009, 339, b3956-b3956.	2.4	1
420	Efficacy of 5HT4-Agonists in Non-Diarrhea Predominant Irritable Bowel Syndrome. American Journal of Gastroenterology, 2008, 103, S478.	0.2	1
421	Prognosis of patients with Rome IVâ€defined versus physicianâ€diagnosed irritable bowel syndrome: Longitudinal followâ€up study. Neurogastroenterology and Motility, 2021, , e14282.	1.6	1
422	Efficacy of Ondansetron for Irritable Bowel Syndrome With Diarrhea. American Journal of Gastroenterology, 2021, 116, 428-429.	0.2	1
423	Irritable bowel syndrome. Clinical Evidence, 2010, 2010, .	0.2	1
424	The Natural History of Sporadic Duodenal Adenomas and Risk of Synchronous Colonic Adenomas. Gastrointestinal Endoscopy, 2004, 59, P170.	0.5	0
425	Electronic Clinical Challenges and Images in GI. Gastroenterology, 2007, 133, e3-e4.	0.6	0
426	Balancing the risk of chronic gastrointestinal bleeding and thromboembolic events in a patient with a metallic aortic valve. Clinical Medicine, 2008, 8, 461-462.	0.8	0
427	Is laparoscopic surgery cost-effective?. Nature Reviews Gastroenterology and Hepatology, 2009, 6, 695-696.	8.2	0
428	PWE-038â€...Adalimumab therapy for infliximab failures in Crohn's disease. A single-centre UK experience. Gut, 2010, 59, A99.3-A100.	6.1	0
429	PTU-055â€...Safety and tolerability of combination therapy for chronic hepatitis C: the Leeds experience: Abstract PTU-055. Gut, 2010, 59, A71.1-A71.	6.1	0
430	PTU-057â€...Predictors of response to combination therapy for chronic hepatitis C: the Leeds experience. Gut, 2010, 59, A71.3-A72.	6.1	0
431	PTU-056â€...Efficacy of combination therapy for chronic hepatitis C: the Leeds experience. Gut, 2010, 59, A71.2-A71.	6.1	0
432	Low Yield of Colonoscopy in Individuals With Suspected Irritable Bowel Syndrome?. American Journal of Gastroenterology, 2010, 105, 2508-2509.	0.2	0

#	ARTICLE	IF	CITATIONS
433	Disease activity and venous thromboembolism in inflammatory bowel disease. <i>Lancet</i> , The, 2010, 375, 1690.	6.3	0
434	<i>Helicobacter pylori</i> eradication. <i>Lancet</i> , The, 2011, 378, 313.	6.3	0
435	Celiac disease and hypertransaminasaemia: a systematic review and meta-analysis. <i>Gut</i> , 2011, 60, A18-A18.	6.1	0
436	Efficacy of tegaserod for the treatment of chronic idiopathic constipation: systematic review and meta-analysis. <i>Gut</i> , 2011, 60, A154-A154.	6.1	0
437	Efficacy of lubiprostone in the treatment of chronic idiopathic constipation: systematic review and meta-analysis. <i>Gut</i> , 2011, 60, A164-A165.	6.1	0
438	Predictors of response and loss of response to infliximab therapy for crohn's disease: a large UK single centre experience. <i>Gut</i> , 2011, 60, A218-A218.	6.1	0
439	Low Yield of Colonoscopy for Melaena Following a Normal Upper Gastrointestinal Endoscopy: A 5-year Analysis. <i>Gut</i> , 2011, 60, A127-A127.	6.1	0
440	Adverse events associated with infliximab therapy in a large single centre UK cohort. <i>Gut</i> , 2011, 60, A217-A218.	6.1	0
441	Granulocyte and monocyte adsorptive apheresis in the management of ulcerative colitis: authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 289-289.	1.9	0
442	Potential role of granulocyte/monocyte adsorptive apheresis for ulcerative colitis with concomitant CMV infection: authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 498-498.	1.9	0
443	Response to Atreja et al.. <i>American Journal of Gastroenterology</i> , 2011, 106, 2046.	0.2	0
444	Response to Yang et al.. <i>American Journal of Gastroenterology</i> , 2011, 106, 2044.	0.2	0
445	Reply to Akobeng. <i>American Journal of Gastroenterology</i> , 2011, 106, 1857-1858.	0.2	0
446	Rome III criteria for functional gastrointestinal disorders: too much overlap to be useful?. <i>Gut</i> , 2011, 60, A25-A25.	6.1	0
447	Response to Doherty and Moss. <i>American Journal of Gastroenterology</i> , 2012, 107, 487-488.	0.2	0
448	Response to Kayhan et al.. <i>American Journal of Gastroenterology</i> , 2012, 107, 321-322.	0.2	0
449	OC-151â€¦Prevalence of, and predictors of, a positive SEHCAT scan for bile acid diarrhoea in outpatients with chronic diarrhoea. <i>Gut</i> , 2012, 61, A65.2-A65.	6.1	0
450	PWE-059â€¦Prevalence of gastro-esophageal reflux disease in individuals with irritable bowel syndrome: a systematic review and meta-analysis: Abstract PWE-059 Table 1. <i>Gut</i> , 2012, 61, A321.1-A321.	6.1	0

#	ARTICLE	IF	CITATIONS
451	PWE-060...Effect of gender on prevalence and subtype of irritable bowel syndrome: a systematic review and meta-analysis. <i>Gut</i> , 2012, 61, A321.2-A321.	6.1	0
452	Treatment of <i>Helicobacter pylori</i> in Latin America. <i>Lancet</i> , The, 2012, 379, 407.	6.3	0
453	Hypertransaminasaemia and coeliac disease: authors'™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 203-204.	1.9	0
454	A Patient With Chronic Diarrhea of Unknown Cause. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, e27-e28.	2.4	0
455	Don't forget about constipation with opioid treatment of chronic non-cancer pain. <i>BMJ</i> , The, 2013, 347, f4492-f4492.	3.0	0
456	PTH-084...Endoscopic and Histological Activity as Predictors of Relapse in Patients Undergoing Surveillance Colonoscopy for Ulcerative Colitis: Abstract PTH-084 Table 1. <i>Gut</i> , 2013, 62, A245.2-A245.	6.1	0
457	PTU-136...Prevalence of Functional Gastrointestinal Disorders in Consecutive New Patient Referrals to a Gastroenterology Clinic: Abstract PTU-136 Table 1. <i>Gut</i> , 2013, 62, A102.2-A103.	6.1	0
458	PTH-194...A Retrospective Analysis of Glucose-Hydrogen Breath test for Small Intestine Bacterial Overgrowth in a Teaching Hospital. <i>Gut</i> , 2013, 62, A290.2-A291.	6.1	0
459	PWE-153...Association...Between Constipation and Colorectal Cancer: Systematic Review and Meta-Analysis of Observational Studies. <i>Gut</i> , 2013, 62, A193.2-A193.	6.1	0
460	PTH-199...Prevalence of Organic Disorders in Consecutive New Patients Meeting Criteria for IBS in a Gastroenterology Clinic. <i>Gut</i> , 2013, 62, A292.3-A293.	6.1	0
461	Editorial: the overlap of atopy and functional gastrointestinal disorders in primary care - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1244-1245.	1.9	0
462	PWE-177...A Systematic Review Of Antidepressants In Irritable Bowel Syndrome: A Qualitative Analysis. <i>Gut</i> , 2014, 63, A203.1-A203.	6.1	0
463	PWE-098...Earlier Use Of Azathioprine In Ulcerative Colitis Does Not Alter Subsequent Need For Hospitalisation, Biologic Therapy, Or Colectomy. <i>Gut</i> , 2014, 63, A167.1-A167.	6.1	0
464	PWE-185...Beliefs About Management Of Irritable Bowel Syndrome In Primary Care: Cross-sectional Survey: Abstract PWE-185 Table 1. <i>Gut</i> , 2014, 63, A207.1-A207.	6.1	0
465	PTH-106...Bile Acid Diarrhoea Masquerades As Diarrhoea-predominant Irritable Bowel Syndrome: Results From A Dual Centre Prospective Study. <i>Gut</i> , 2014, 63, A257.2-A258.	6.1	0
466	Letter: irritable bowel syndrome is significantly associated with somatisation - authors'™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 791-792.	1.9	0
467	PTU-068...Outcomes of disease modifying therapy delivered to crohn's™ disease patients following intestinal resection: Abstract PTU-068 Table 1. <i>Gut</i> , 2015, 64, A90.1-A90.	6.1	0
468	PTU-067...How are postoperative crohn's™ patients followed up? a retrospective analysis from a tertiary referral centre. <i>Gut</i> , 2015, 64, A89.2-A89.	6.1	0

#	ARTICLE	IF	CITATIONS
469	PTU-066 Characteristics and outcomes of patients undergoing second intestinal resection for crohn's disease in a tertiary referral centre. <i>Gut</i> , 2015, 64, A89.1-A89.	6.1	0
470	PTU-089 Are clinical indices of inflammatory bowel disease activity superior to patient opinion at predicting activity as defined by faecal calprotectin?: Abstract PTU-089 Table 1. <i>Gut</i> , 2015, 64, A100.1-A100.	6.1	0
471	PTU-090 Prevalence and impact of irritable bowel type-symptoms in quiescent inflammatory bowel disease. <i>Gut</i> , 2015, 64, A100.2-A100.	6.1	0
472	PTU-065 The influence of smoking on need for surgery and post-operative outcomes in crohn's disease. <i>Gut</i> , 2015, 64, A88.2-A89.	6.1	0
473	PTU-176 Systematic review with meta-analysis: prevalence of bile acid malabsorption in irritable bowel syndrome with diarrhoea. <i>Gut</i> , 2015, 64, A140.2-A141.	6.1	0
474	PTU-086 Outcomes of all surgery for ulcerative colitis over a 12-month period at a tertiary referral ibd unit. <i>Gut</i> , 2015, 64, A98.2-A99.	6.1	0
475	Pinaverium in Irritable Bowel Syndrome: Old Drug, New Tricks?. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1548-1549.	2.4	0
476	Comment on "A randomized clinical trial of <i>Saccharomyces cerevisiae</i> versus placebo in the irritable bowel syndrome" by Guillaume Pineton de Chambrun et al. [ <i>Digestive and Liver Disease</i> 2015;47:119-124]. <i>Digestive and Liver Disease</i> , 2015, 47, 437.	0.4	0
477	Irritable Bowel Syndrome and Colorectal Neoplasia: Cause and Effect or Chance Association?. <i>Gastroenterology</i> , 2015, 149, 502-503.	0.6	0
478	Is it Time to Rethink Screening of Individuals With Symptoms of Irritable Bowel Syndrome for Celiac Disease?. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1944-1945.	2.4	0
479	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 779.	2.4	0
480	Mo1635 Efficacy of Linaclotide in Constipation-Predominant Irritable Bowel Syndrome in Routine Clinical Practice: A Multicentre Experience. <i>Gastroenterology</i> , 2016, 150, S737-S738.	0.6	0
481	Letter: biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1246-1246.	1.9	0
482	Derivation and Validation of a Panel of Exhaled Volatile Organic Compounds in Differentiating Irritable Bowel Syndrome From Health. <i>Gastroenterology</i> , 2016, 151, 1245-1246.	0.6	0
483	Response to Levenstein and Prantera. <i>American Journal of Gastroenterology</i> , 2016, 111, 1499.	0.2	0
484	PTU-128 Prevalence and Management of Irritable Bowel Syndrome Seen in Colorectal Surgery and Gastroenterology Clinics. <i>Gut</i> , 2016, 65, A120.1-A120.	6.1	0
485	PTU-137 Enhanced Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by History and Diagnostic Evaluation: Abstract PTU-137 Table 1. <i>Gut</i> , 2016, 65, A125.1-A125.	6.1	0
486	Letter: deleterious effects of smoking on post-operative Crohn's disease authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1248-1248.	1.9	0

#	ARTICLE	IF	CITATIONS
487	PTU-117â€¦Screening for Coeliac Disease in Irritable Bowel Syndrome Is Still Worthwhile: An Updated Systematic Review and Meta-Analysis. <i>Gut</i> , 2016, 65, A113.2-A113.	6.1	0
488	Antibiotic use and subsequent development of functional gastrointestinal disorders: effect of symptom-reporting and consultation behavior. <i>Neurogastroenterology and Motility</i> , 2016, 28, 449-450.	1.6	0
489	Validation of a Serum Biomarker for Irritable Bowel Syndrome: Is an Accurate, Single Biomarker Test Possible?. <i>Gastroenterology</i> , 2016, 150, 277-278.	0.6	0
490	Editorial: latent class analysis to improve confidence in the diagnosis of <sc>IBS</sc> â€” authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1268-1269.	1.9	0
491	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1315-1316.	2.4	0
492	No Detrimental Effect of Oats on Symptoms, Histological Parameters, Serological Tests, or Quality of Life in Celiac Disease: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2017, 152, S481.	0.6	0
493	Letter: <sc>NICE</sc> referral criteria for lower gastrointestinal alarm features â€” not ideal but not poor either. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1176-1176.	1.9	0
494	Editorial: probiotics in inflammatory bowel diseaseâ€”wrong organisms, wrong disease, or flawed concepts? Authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 633-634.	1.9	0
495	Female Gender, Somatization and Presence of IBS-Type Symptoms Predicts Dyspareunia in Patients with IBD. <i>Gastroenterology</i> , 2017, 152, S795.	0.6	0
496	PWE-053â€¦Outcomes of anti-tnf versus vedolizumab therapy for ulcerative colitis: the leeds experience. , 2017, , .		0
497	Proton pump inhibitors and oesophageal cancer: Flawed methodology and false alarms. <i>Cancer Epidemiology</i> , 2018, 54, 137-138.	0.8	0
498	Defining the functional gastrointestinal disorders is challenging: are clinical symptoms alone sufficient?. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 140-140.	0.6	0
499	Efficacy of linaclotide in irritable bowel syndrome with constipation: Realâ€”world data. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13328.	1.6	0
500	PWE-139â€¦Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and network meta-analysis. , 2018, , .		0
501	IDDF2018-ABS-0047â€¦Acupuncture and related therapies for treating irritable bowel syndrome: overview of systematic reviews and network meta-analysis. , 2018, , .		0
502	Reply. <i>Gastroenterology</i> , 2018, 155, 1652-1653.	0.6	0
503	Response to Letter by Moulton et al.. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e99-e99.	0.9	0
504	OWE-13â€¦Consequences of using the rome IV criteria to diagnose irritable bowel syndrome. , 2019, , .		0



#	ARTICLE	IF	CITATIONS
505	PWE-076â€¦Efficacy of Pharmacological Therapies in Patients with Irritable Bowel Syndrome with Diarrhoea: Network Meta-analysis. , 2019, , .		0
506	Crohnâ€™s Disease Connectome Conundrums: Relevance to the Prevalence and Management of Mood Disorders. Gastroenterology, 2019, 157, 1429-1430.	0.6	0
507	Bloating and Abdominal Distention. , 2020, , 380-385.		0
508	Bugs and the Brain in Inflammatory Bowel Disease: A Novel Treatment Target?. Clinical Gastroenterology and Hepatology, 2021, 19, 1738-1739.	2.4	0
509	O63â€¦Gastrointestinal symptom-specific anxiety and symptom severity in irritable bowel syndrome: new insights from factor analysis. , 2021, , .		0
510	In the Face of Adversity: Is Resilience a New Target for Inflammatory Bowel Disease Therapy?. Gastroenterology, 2021, 160, 466-467.	0.6	0
511	Editorial: recognising the efficacy of licensed drug therapies for irritable bowel syndrome on bloatingâ€™ a step in the right direction for targeted treatment? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 198-199.	1.9	0
512	P326â€¦Identification of novel subgroups in irritable bowel syndrome using latent class analysis: beyond stool form. , 2021, , .		0
513	Determining the Optimum Outcome for Trials Evaluating Symptom Improvement in Functional Gastrointestinal Disorders. American Journal of Gastroenterology, 2010, 105, S492-S493.	0.2	0
514	Prevalence of Anxiety and Depression in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. SSRN Electronic Journal, 0, , .	0.4	0
515	Efficacy of Senna and Magnesium Oxide for the Treatment of Chronic Idiopathic Constipation. American Journal of Gastroenterology, 2021, 116, 1352-1353.	0.2	0
516	Constipation in adults. Clinical Evidence, 2015, 2015, .	0.2	0
517	Overlap Between Irritable Bowel Syndrome and Inflammatory Bowel Disease. Gastroenterology and Hepatology, 2020, 16, 211-213.	0.2	0
518	Editorial: risky business. What do sufferers' perceptions of risk from interventions for IBS really mean? Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 1220-1221.	1.9	0
519	Editorial: will clusters for anxiety, depression, sleep disturbance and fatigue symptoms predict treatment outcomes in functional dyspepsia? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 652-653.	1.9	0
520	Editorial: coâ€™morbidity gastrointestinal conditions are an important consideration in IBS managementâ€™ authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 1153-1154.	1.9	0
521	Letter in response to Black <i>et al</i>. (2020): Authorsâ€™ Reply. Neurogastroenterology and Motility, 2022, 34, e14388.	1.6	0
522	Editorial: estimating the costs of care in irritable bowel syndromeâ€™ a necessary step to enhance valueâ€™based care for a highâ€™prevalence, lowâ€™cost condition. Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 1590-1591.	1.9	0